Anest. intenziv. Med. 2006;17(1):6-13

Antifibrinolytic agents in off-pump cardiac surgery: analysis of blood loss, safety and cost-effectivenessAnaesthesiology - Original Paper

T. Vaněk1, M. Jareš1, R. Fajt1, Z. Straka1, M. Malý2
1 Kardiochirurgická klinika, Univerzita Karlova, 3. LF a FNKV, Praha
2 Oddělení biostatistiky a informatiky, SZÚ, Praha

Objective:
To compare the haemostatic effects of fibrinolytic inhibitors (tranexamic acid, aprotinin) vs. placebo in off-pump coronary artery bypass surgery and to evaluate the impact of this therapy on cost-effectiveness.

Design:
Prospective, randomized, double-blind study.


Setting:
University Teaching Hospital, Prague, Czech Republic.


Material and Method:
100 patients were enrolled in the study and 91 of them were assessed (group A, n = 32, tranexamic acid 1 g before skin incision followed by continuous infusion at 200 mg/h; group B, n = 29, aprotinin 1,000,000 IU before skin incision and 250,000 IU/h afterwards; group C, n = 30, placebo).

Results:
Highly significant inter-group differences were found in the cumulative blood loss within 4 h (geometric means [95% confidence intervals] - group A: 89.3 [72.7, 109.8] mL, group B: 72.3 [49.2, 106.3] mL and group C: 192.3 [151.8, 243.5] mL) (P < 0.001), within 8 h (group A: 152.1 [120.7, 191.6] mL, group B: 130.3 [88.1, 192.8] mL and group C: 283.8 [226.0, 356.3] mL) (P = 0.001), and within 24 h postoperatively (group A: 410.3 [337.6, 498.6] mL, group B: 345.8 [256.0, 398.2] mL and group C: 619.8 [524.3, 732.8] mL) (P < 0.001). At all time points, group C (placebo) was significantly distinct from the groups treated with fibrinolytic inhibitors (groups A, B). However, no essential differences between groups A and B were found. Treated groups did not demonstrate postoperative increase in mean levels of myocardial enzymes compared with group C. No statistically significant inter-group difference was found in the number of re-transfused patients (either packed red blood cells, P = 0.119, or fresh-frozen plasma, P = 0.118) during the first 24 h postoperatively, but the number of re-transfused patients during the hospital stay was statistically significantly higher in group C compared with group B (P = 0.002). Cost effectiveness of the antifibrinolytic agent and blood product treatment seems to be on average the most favourable in the tranexamic acid group.

Conclusion:
Both tranexamic acid and aprotinin seem to be similarly effective in the reduction of postoperative blood loss in off-pump cardiac surgery. Tranexamic acid appears to be a cost-effective and safe alternative to aprotinin.

Keywords: tranexamic acid; aprotinin; cardiac surgical procedures; off-pump coronary artery bypass

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaněk T, Jareš M, Fajt R, Straka Z, Malý M. Antifibrinolytic agents in off-pump cardiac surgery: analysis of blood loss, safety and cost-effectiveness. Anest. intenziv. Med. 2006;17(1):6-13.
Download citation

References

  1. Nuttall, G. A., Oliver, W. C., Santrach, P. J. et. al. Efficiacy of a simple intraoperative transfusion algorithm for non-erythrocyte component utilization after cardiopulmonary bypass. Anaesthesiology, 2001, 94, p. 773-781. Go to original source... Go to PubMed...
  2. Despotis, G. J., Filos, K. S., Zoys, T. N., Hogue, C. W., Jr., Spitznagel, E., Lappas, D. G. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariete analysis in cardiac surgical patients. Anesth. Analg., 1996, 82, p. 13-21. Go to original source... Go to PubMed...
  3. Biglioli, P., Cannata, A., Alamanni, F. et. al. Biological effects of off-pump vs. on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress. Eur. J. Cardio-thoracic Surg., 2003, 24, p. 260-269. Go to original source... Go to PubMed...
  4. Cvachovec, K., Horáček, M., Vislocký, I. A retrospective survey of fibrinolysis as an indicator of poor outcome after cardiopulmonary bypass and a possible early sign of systemic inflammation syndrome. Eur. J. Anaesthesiol., 2000, 17, p. 173-176. Go to original source... Go to PubMed...
  5. Levi, M., Cromheecke, M. E., de Jonge, E. et. al. Pharmacological strategies to decrease blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet, 1999, 354, p. 1940-1947. Go to original source... Go to PubMed...
  6. Alderman, E. L., Levy, J. H., Rich, J. B. et. al. Analyses of coronary graft patency after aprotinin use: results from the international multicenter aprotinin graft patency experience (IMAGE) trial. J. Thorac. Cardiovasc. Surg., 1998, 116, p. 716-730. Go to original source... Go to PubMed...
  7. Casati, V., Gerly, Ch., Franco, A. et. al. Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study. Ann. Thorac. Surg., 2001, 72, p. 470-475. Go to original source... Go to PubMed...
  8. Englberger, L., Markart, P., Eckstein, F. S., Immer, F. F., Berdat, P. A., Carrel, T. P. Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. Eur. J. Cardio-thorac. Surg., 2002, 22, p. 545-551. Go to original source... Go to PubMed...
  9. Jareš, M., Vaněk, T., Straka, Z., Brůček, P. Tranexamic acid reduces bleeding after off-pump coronary artery bypass grafting. J. Cardiovasc. Surg. (Torino), 2003, 44, p. 205-208. Go to PubMed...
  10. Casati, V., Della Valle, P., Benussi, S. et. al. Effects of tranexamic acid in postoperative bleeding and related hematological variables in coronary surgery: a comparison between on-pump and off-pump techniques. J. Thorac. Cardiovasc. Surg., 2004, 128, p. 83-91. Go to original source... Go to PubMed...
  11. Vaněk, T., Brůček, P., Straka, Z. Fast track as a routine for open-heart surgery. Eur. J. Cardio-thorac. Surg., 2001, 21, p. 369-370. Go to original source... Go to PubMed...
  12. Vaněk, T., Jareš, M., Fajt R. et. al. Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Eur. J. Cardio-thorac. Surg., 2005, 28, p. 563-568. Go to original source... Go to PubMed...
  13. Hekmat, K., Zimmermann, T., Kampe, S. et. al. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomized, double-blind trial. Curr. Med. Res. Opin., 2004, 20, p. 121-126. Go to original source... Go to PubMed...
  14. Green, J. A., Reynolds, P. S., Makhoul, K. et. al. Potential financial savings of a "bloodless" cardiac surgery initiative. Anesth. Analg., 2003, 96, Abstracts SCA 17. Go to PubMed...
  15. Robinson, D., Bliss, E. A model of direct and indirect effects of aprotinin administration on the overall costs of coronary revascularization surgery in a university teaching hospital cardiothoracic unit. Clin. Ther., 2002, 24, p. 1677-1689. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.